31st week of 2011 patent applcation highlights part 48 |
Patent application number | Title | Published |
20110190164 | CHIMERIC FUSION PROTEINS AND VIRUS LIKE PARTICLES FROM BIRNAVIRUS VP2 - The field of the invention refers to chimeric Virus Like Particles (VLP) derived from Birnavirus chimeric VP2 protein. In particular, the invention refers to chimeric VP2 fusion proteins which incorporate insertions and/or substitutions with one or more amino acids or particular peptide of interest while maintaining the capacity to assemble in the form of VLP. The invention identifies particular insertion and/or substitutions sites within VP2 P loop regions and outside said P loop regions. The invention also incorporates methods for the identification of preferred insertion and substitution sites within VP2 for the incorporation of particular amino acids and peptides of interest. The resulting chimeric VLP are of interest in the design of therapeutic and prophylactic vaccines as well as in the design of drug delivery systems, carriers for DNA and RNA in gene therapy, as targeted agents, in the development of antitoxins, and as diagnostic reagents. | 2011-08-04 |
20110190165 | HIGH THROUGHPUT METHODS OF IDENTIFYING NEUTRAL LIPID SYNTHASES - The present invention relates to high throughput methods of identifying neutral lipid synthases. The invention includes a method of positively selecting yeast cells expressing recombinant neutral lipid synthases, and quantifying the enzyme activities of the recombinant neutral lipid synthases using a fluorescence in situ assay. | 2011-08-04 |
20110190166 | ERYTHROID PROGENITOR CELLS AND METHODS FOR PRODUCING PARVOVIRUS B19 THEREIN - The disclosure relates to erythroid progenitor cells and methods for producing parvovirus B 19 in the cells. The invention includes transformed and/or immortalized CD36+ erythroid progenitor cells permissive for B19 infection and methods for producing useful quantities of B 19 in the cells described herein. Infectious virus produced by the cells of the disclosure is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B 19 infections. | 2011-08-04 |
20110190167 | Electromagnetically responsive element with self resonant bodies - An electromagnetically responsive element includes an arrangement of self-resonant bodies, such as atoms or quantum dots that form an effective dielectric constant, typically at or near a resonance. | 2011-08-04 |
20110190168 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is Closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is Widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 2011-08-04 |
20110190169 | SIMULTANEOUS ASSAY FOR DETERMINING DRUGS - Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles. | 2011-08-04 |
20110190170 | COMPOSITIONS FOR USE IN IDENTIFICATION OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to identification of antibiotic-resistant bacteria and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis. | 2011-08-04 |
20110190171 | LOW TOXICITY SHALE HYDRATION INHIBITION AGENT AND METHOD OF USE - A low toxicity composition and method of reducing the swelling of clay in well comprising circulating in the well a water-based fluid comprising a functionally effective concentration of the additive formed from the following reaction of a tertiary amine of the following general formula: | 2011-08-04 |
20110190172 | GELLED HYDROCARBONS FOR OILFIELD PROCESSES AND METHODS OF USE - Gelled liquid hydrocarbons and methods for gelling hydrocarbons and treating subterranean wellbores employ a phosphorus compound of the formula: | 2011-08-04 |
20110190173 | ACIDIC TREATMENT FLUIDS AND ASSOCIATED METHODS - Treatment fluids that comprise a phosphorus component useful for inhibiting metal corrosion in acidic environments and associated methods of use are provided. An example of a method of using such treatment fluids may comprise providing a treatment fluid that comprises: an aqueous base fluid, a weak acid or salt thereof, and a phosphorus component, and introducing the treatment fluid into a subterranean formation. | 2011-08-04 |
20110190174 | Styrylphenol Alkoxylate Sulfate as a New Surfactant Composition for Enhanced Oil Recovery Applications - A method of making a styryl phenol alkoxylate sulfate surfactant by alkoxylation of a styryl phenol using propylene oxide (PO) and/or ethylene oxide (EO) followed by a sulfation reaction. The styrylphenol alkoxylate sulfate surfactant of the present invention is made by a facile and inexpensive method. The large hydrophobe surfactants of the present invention find uses in EOR applications where it is used for solubilization and mobilization of oil optionally containing asphaltene, and for environmental cleanup. Further, the unsulfated version of the large hydrophobe styrylphenol alkoxylate surfactant of the present invention can be used as an ultra-high molecular weight non-ionic surfactant. | 2011-08-04 |
20110190175 | USE OF SURFACTANT MIXTURES FOR TERTIARY MINERAL OIL EXTRACTION - The use of a surfactant mixture comprising at least one surfactant having a hydrocarbon radical composed of from 12 to 30 carbon atoms and at least one cosurfactant having a branched hydrocarbon radical composed of from 6 to 11 carbon atoms for tertiary mineral oil extraction. | 2011-08-04 |
20110190176 | Cleaning and Lubricating Wipes - The Invention relates to a product comprising of an absorbent wipe and lubricating oil. The lubricating oil is impregnated into the wipe resulting in an oil-saturated wipe that can be used to clean and lubricate drive chains and gears. The oil-saturated wipe allows the user to clean and lubricate simultaneously, combining the typical 2 step process into one easy and convenient step. The oil saturated wipe also reduces the typical waste normally resulting from dripping oil onto the drive chain and prevents the oil from spilling onto unwanted parts that are in close proximity to the drive chain. | 2011-08-04 |
20110190177 | LUBRICATING GREASES AND PROCESS FOR THEIR PRODUCTION - A process includes adding an effective amount of a calcium lignin sulfonate to a thickened base grease to form a lubricating grease wherein the calcium lignin sulfonate has a molecular weight of at least 10,000 g/mol; the calcium lignin sulfonate has a water content of less than about 0.5 wt %; the effective amount is from about 1 wt % to about 20 wt % based upon the weight of the lubricating grease; the thickened base grease is obtained from a grease forming process or a lubricating paste; and the lubricating grease has a water solubility below about 3 wt %, as determined by a water wash out-test. | 2011-08-04 |
20110190178 | Solid lubricant and sliding member - Lead-free solid lubricant to be embedded in pores or grooves formed at a sliding surface of a sliding member body, comprising 20 to 40% by weight of at least one wax selected from hydrocarbon waxes, higher-fatty acids, esters of higher-fatty acid and amides of higher-fatty acid, 20 to 40% by weight of melamine cyanurate, and 20 to 50% by weight of a polytetrafluoroethylene resin. The lubricant exhibits sliding properties identical to or higher than those of lead-containing solid lubricants, even under high load conditions. | 2011-08-04 |
20110190179 | AQUEOUS LUBRICANT EMULSION FOR MEDICAL OR APPARATUS AND A METHOD OF WASHING - An aqueous lubricant emulsion for medical or food apparatus, comprising: (a) 5 wt % to 30 wt % of a mineral oil; (b) 5 wt % to 30 wt % of an emulsifier system consisting of two emulsifiers selected from the group consisting of sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, oleyl alcohol ether, triethanolamine oleate, wherein the mass ratio of the two emulsifiers is in a range of 2:8 to 8:2; (c) 0.5 wt % to 5 wt % of one or more coemulsifiers selected from the group consisting of fatty alcohols, long-chain fatty acids, and diisooctyl succinate sulfonates; and (d) the balance of water. A method for washing medical or food apparatus including the step of subjecting the medical or food apparatus to a treatment using the lubricant emulsion according to the invention after a washing step for the medical or food apparatus is also described. | 2011-08-04 |
20110190180 | Composition Containing Heterocyclic Compounds and a Method of Lubricating an Internal Combustion Engine - The present Invention relates to the use of a compound in a lubricating composition as an engine oil antiwear and/or extreme pressure agent, wherein the compound is a heterocycle having a hydrocarbyl group containing 6 to 40 carbon atoms, wherein the heterocycle is either (i) a heterocycle compound having a functional group selected from the group consisting of at least one of an ester, an amide, a salt and an acid, or (ii) a pyrimidine. | 2011-08-04 |
20110190181 | LUBRICATING COMPOSITION COMPRISING POLY(HYDROXYCARBOXYLIC ACID) AMIDE AND DETERGENT - The present invention provides a lubricating composition comprising: a base oil; one or more poly (hydroxycarboxylic acid) amide salt derivatives having Formula (III): [Y—CO [O-A-CO] | 2011-08-04 |
20110190182 | Novel Copolymers and Lubricating Compositions Thereof - The present invention relates to a copolymer comprising units derived from monomers (i) an α-olefin and (ii) an ethylenically unsaturated carboxylic acid or derivatives thereof esterified with a primary alcohol branched at the β- or higher position, wherein the copolymer has a reduced specific viscosity of up to 0.08. The invention further provides for a lubricating composition containing said copolymer. The invention further provides a method and use of controlling viscosity index by supplying to an oil of lubricating viscosity the copolymer with pendant groups. In addition, the copolymer of the present invention may be useful as a base oil replacement. | 2011-08-04 |
20110190183 | LUBRICATING OIL COMPOSITION - The present invention provides a lubricating oil composition having a low traction coefficient that can reduce the friction between parts such as gear teeth surfaces, exposed to elastohydrodynamic lubrication conditions to attain energy saving properties and high efficiency, suitable for use in manual, automatic and continuously variable transmissions of automobiles or industrial gear systems. The low traction coefficient lubricating oil composition comprises a lubricating base oil containing (A) a partial ester of a polyhydric alcohol and a carboxylic acid in an amount of 0.1 to 80 percent by mass on the basis of the total mass of the base oil and having a kinematic viscosity at 100° C. of 1 to 15 mm | 2011-08-04 |
20110190184 | Lubricants for air conditioning systems - Lubricants for air conditioning systems in hybrid vehicles can be high dielectric lubricants. | 2011-08-04 |
20110190185 | Lubricating oil additive and lubricating oil composition containing same - An overbased salt of an oligomerized alkylhydroxyaromatic compound for use in a lubricating oil composition is disclosed, wherein the alkyl group of the alkylhydroxyaromatic compound is derived from an olefin mixture comprising propylene oligomers having an initial boiling point of at least about 195° C. and a final boiling point of greater than 325° C. and up to about 400° C. as measured by ASTM D86. Also disclosed is a propylene oligomer having an initial boiling point of at least about 195° C. and a final boiling point of greater than 325° C. and up to about 400° C. as measured by ASTM D8, wherein the propylene oligomer contains a distribution of carbon atoms that comprise at least about 50 weight percent of C | 2011-08-04 |
20110190186 | SKIN CLEANSING SYSTEM AND METHOD - A cleansing composition for cleansing skin, especially for removing grease from skin. A cleaning composition of the present invention may also be used in ready-to-use (or in-use) kits, such as two component kits, suitable for cleansing skin. | 2011-08-04 |
20110190187 | ORGANIC RESIDUE REMOVER COMPOSITION - Organic residue remover composition useful to remove from very oily type soils to very watery contaminants from various surfaces, obtained by mixing: component (a): at least one water insoluble hydrophobic compound, component (b): at least one water soluble glycol ether, component (c): at least one water insoluble glycol ether, component (d): at least one aromatic alcohol, component (e): at least one surfactant, optionally component (f): at least one hydrotrope, and component (g): water, wherein each component or an ingredient thereof is different from the other components or ingredients thereof in the organic residue remover composition. | 2011-08-04 |
20110190188 | BLEACH COMPOSITIONS - Laundry or cleaning composition comprising: (a) a catalytically effective amount, preferably from about 1 ppb to about 99.9%, of a transition-metal bleach catalyst which is a complex of a transition-metal and a cross-bridged macropolycyclic ligand; and (b) at least about 0.1% of one or more laundry or cleaning adjunct materials, preferably comprising an oxygen bleaching agent. Preferred compositions are laundry compositions and automatic dishwashing detergents which provide enhanced cleaning/bleaching benefits through the use of such catalysts. | 2011-08-04 |
20110190189 | LIQUID DETERGENT COMPOSITION - A composition comprising a liquid portion comprising at least one surfactant, at least one suspending agent, and at least one viscosity control agent, wherein the composition has an apparent viscosity under a shear stress of 0.5 Pa of at least about 1,000 Pa·s; and the composition has an apparent viscosity under a shear stress of 100 Pa of less than about 10 Pa·s. The composition is capable of suspending materials, but it still has desired rheological properties. | 2011-08-04 |
20110190190 | Novel Linear Polydimethylsiloxane-Polyether Copolymers with Amino and/or Quaternary Ammonium Groups and Use Thereof - Household care compositions having a linear polydimethylsiloxane-polyether copolymers with amino and/or quaternary ammonium groups, obtainable by the reaction of organopolysiloxanes functionalized with secondary aminoalkyl groups with the reaction products formed from compounds containing epoxy groups and amines, the use thereof and process for preparation thereof. | 2011-08-04 |
20110190191 | Laundry Composition with Encapsulated Liquid Benefit Agent - A process for making aggregate granules comprising encapsulates or microcapsules of liquid benefit agent, preferably perfume, the process comprising the steps of: a) providing a powdered and/or granulated laundry composition comprising detergent particles selected from surfactants, fabric softeners and/or detergency builders; b) preparing a slurry comprising water, optional soluble materials, and encapsulates of liquid benefit agent; c) spraying the slurry prepared in step b) onto the laundry composition provided in step a) using a high rate of spray to create droplets larger than 70 micron in order to form aggregate granules of liquid benefit agent encapsulates anchored to detergent particles. Also, to particulate detergent compositions including the aggregate granules obtainable by the process and use of the compositions in laundry processes. | 2011-08-04 |
20110190193 | TREATMENT OF ENDOTHELIAL DYSFUNCTION IN DIABETIC PATIENTS - A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL). | 2011-08-04 |
20110190194 | PREPARATION AND COMPOSITION OF INTER-ALPHA PROTEINS FROM BLOOD - The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IαIp) and compositions thereof from blood. | 2011-08-04 |
20110190195 | MULTI-COMPONENT ANTIOXIDANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR REDUCING OR PREVENTING OXIDATIVE STRESS - An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effecting antioxidation; and at least two peptide bonds, each being cleavable by at least one intracellular peptidase; and (b) a first hydrophobic or non-charged moiety being attached to an amino terminal of the peptide via a first bond and a second hydrophobic or non-charged moiety being attached to a carboxy terminal of the peptide via a second bond, the first hydrophobic or non-charged moiety and the second hydrophobic or non-charged moiety are selected so as to provide the antioxidant compound with membrane miscibility properties for permitting the antioxidant compound to cross cellular membranes; wherein cleavage of the at least two peptide bonds by the at least one intracellular peptidase results in generation of a plurality of antioxidant species, each including one of the cysteine residues having the readily oxidizable sulfhydryl group and which is also active in effecting antioxidation, thereby providing for a plurality of different antioxidant species acting in synergy in exerting antioxidation. | 2011-08-04 |
20110190196 | IMPROVED PEPTIDE MEDIATORS OF CHOLESTEROL EFFLUX - The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation. | 2011-08-04 |
20110190197 | PLANT DERIVED ANTIBIOTIC PEPTIDE RICH IN GLYCINE - The present invention relates to a novel peptide extracted from guava ( | 2011-08-04 |
20110190198 | PEPTIDE SEQUNCES, THEIR BRANCHED FORM AND USE THEREOF FOR ANTIMICROBIAL APPLICATIONS - The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof. | 2011-08-04 |
20110190199 | Combination Therapy for Tuberculosis - The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (I), (S)—N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles. | 2011-08-04 |
20110190200 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL pH BUFFERS - Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs. | 2011-08-04 |
20110190201 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 2011-08-04 |
20110190202 | Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes - Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof; | 2011-08-04 |
20110190203 | Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 2011-08-04 |
20110190204 | Taxane- and Taxoid-Protein Compositions - Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer. | 2011-08-04 |
20110190205 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide - The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide. | 2011-08-04 |
20110190206 | REDUCING MYOCARDIAL REPERFUSION INJURY BY THE COMBINATION THERAPY OF PROTEIN KINASE A ACTIVATION AND B1-ADRENERGIC RECEPTOR BLOCKADE - Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a β | 2011-08-04 |
20110190207 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 2011-08-04 |
20110190208 | MEDICAL USE OF THE RADICAL SCAVENGER AND ANTIOXIDANT ALPHA-1-MICROGLOBULIN - Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1-microglobulin in the treatment or prophylaxis of diseases or conditions associated with the presences of free radicals and/or free haemoglobin in the subject. | 2011-08-04 |
20110190209 | CONJUGATES HAVING A RELEASABLE LINKAGE - The present invention provides conjugates having a releasable linkage. Methods of making conjugates, and methods for administering conjugates, are also provided. | 2011-08-04 |
20110190210 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 2011-08-04 |
20110190211 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA - A cyclopenta[g]quinazoline derivative, containing an L-Glu-γ-D-Glu dipeptide group, of formula (I): wherein R | 2011-08-04 |
20110190213 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-3 - The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native IL-3 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 2011-08-04 |
20110190214 | Advantageous Salts of Mu-Opiate Receptor Peptides - The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions. | 2011-08-04 |
20110190215 | THERAPEUTIC USE OF PEPTIDES - The amino acid sequences of peptides are disclosed. These peptides, and combinations thereof, are useful, inter alia, for the treatment of obesity, type II diabetes mellitus, hypertension, central nervous system disorders, dementia, Alzheimer's disease, asthma, and cancer, | 2011-08-04 |
20110190216 | MATERIALS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY AND TAXANE-INDUCED PERIPHERAL NEUROPATHY (TIPN) - The present invention concerns materials and methods for treating, inhibiting the progression or, and/or preventing a disorder associated with and/or characterized by neuronal degeneration, such as SMA or TIPN, in a person or animal. One aspect of the invention pertains to a fusion protein comprising: i) an SMN polypeptide portion, or a fragment or variant thereof having SMN biological activity, and ii) a non-toxic BoTN portion, or a fragment or variant thereof capable of providing for receptor-mediated endocytosis in a cell, such as a neuron. In one embodiment, the SMN protein is a human SMN1 protein. In one embodiment, the BoTN portion comprises the BoTN heavy chain, or a fragment or variant thereof capable of providing for receptor-mediated endocytosis in a cell. The non-toxic BoTN portion can optionally comprise a modified and/or hybrid polypeptide that comprises amino acid sequences or polypeptides from non-BoTN proteins or polypeptides and optionally BoTN polypeptides. For example, in one embodiment, a non-toxic BoTN portion of the invention comprises a non-toxic portion of a diphtheria toxin and/or tetanus toxin. | 2011-08-04 |
20110190217 | METHODS FOR TREATING INFLAMMATORY DISORDERS AND TRAUMATIC BRAIN INJURY USING STABILIZED NON-HEMATOPOIETIC EPO SHORT PEPTIDES - The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides. | 2011-08-04 |
20110190218 | BAG-1 PEPTIDE THAT INHIBITS PROSTATE CANCER - The present invention relates to a polypeptide having antitumor properties, to a vector encoding said polypeptide, to a host cell containing said vector, to uses of said polypeptide in the manufacture of a medicament for the treatment of cancer in patients, to a method comprising binding said polypeptide to molecular chaperones, and to a pharmaceutical composition containing said polypeptide. | 2011-08-04 |
20110190219 | TREATING CANCER WITH GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR - Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described. | 2011-08-04 |
20110190220 | Use of Defensin Alpha 1 and/or Defensin Alpha 4, as a Marker for Predicting Treatment Response and/or a Relapse in a Patient Suffering form Chronic Myeloid Leukemia - The present invention pertains to the use of defensin α1 and/or defensin α4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib. | 2011-08-04 |
20110190221 | MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA - The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury. | 2011-08-04 |
20110190222 | Selective Inhibition of Polyglutamine Protein Expression - The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs. | 2011-08-04 |
20110190223 | HEMCM42 NUCLEIC ACIDS - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. | 2011-08-04 |
20110190224 | Non-Viral Delivery of Compounds to Mitochondria - A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described. | 2011-08-04 |
20110190225 | Topical method for prompt relief of severe ascites - A means is provided to make the capsules of cirrhotic or fibrotic livers relatively impermeable to liver tissue fluid or lymph in humans or other mammals suffering from severe chronic ascites or refractory ascites by application of collodion. The means will be useful to decrease the need for liver and combined liver and kidney transplantations | 2011-08-04 |
20110190226 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV - The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4′-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay. | 2011-08-04 |
20110190227 | Antagonists of Prostaglandin D2 Receptors - Described herein are compounds that are antagonists of PGD | 2011-08-04 |
20110190228 | SANITISING COMPOSITIONS - The present invention relates to a sanitising composition, particularly to a sanitising composition for combating undesired microorganisms, especially those present on food products such as salads, poultry, cut fruit, and in hospital environments. There is provided a sanitising composition comprising at least one flavonoid, and at least one a surfactant, wherein the composition is acidic. | 2011-08-04 |
20110190229 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING - A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others. | 2011-08-04 |
20110190230 | Betalain Compositions and Uses Thereof - Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood. | 2011-08-04 |
20110190231 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): | 2011-08-04 |
20110190232 | INSECTICIDAL COMBINATIONS - A method of controlling or preventing damage to a plant, which comprises applying on the plant or a surrounding area thereof a combination comprising (I) abamectin, and (II) cyflumetofen, in any desired sequence or simultaneously. | 2011-08-04 |
20110190233 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE - The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. | 2011-08-04 |
20110190234 | MYCOBACTERIUM MEMBRANE PROTEASE AS A TARGET FOR INHIBITORS OF INTRABACTERIAL pH HOMEOSTASIS - The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the | 2011-08-04 |
20110190235 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 2011-08-04 |
20110190236 | CHEMICAL COMPOUNDS - The present invention features compounds that are prodrugs of HIIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2011-08-04 |
20110190237 | Macrocyclic Prodrug Compounds Useful as Therapeutics - The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or symptoms resulting from neurofibromatosis. | 2011-08-04 |
20110190238 | MODIFICATIONS OF SOLID 3-SN-PHOSPHOGLYCERIDES - Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A | 2011-08-04 |
20110190239 | BMI-1 PROTEIN EXPRESSION MODULATORS - The compounds, pharmaceutical compositions, and methods of using such compounds or compositions thereof described herein are useful for treating a disease modulated by B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein expression. | 2011-08-04 |
20110190240 | NUCLEAR FACTOR KAPPA B PATHWAY INHIBITOR COMPOSITION AND USE OF SAME - An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I)a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds. | 2011-08-04 |
20110190241 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX - Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro. | 2011-08-04 |
20110190242 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE - The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound. | 2011-08-04 |
20110190243 | DIAGNOSIS AND TREATMENT OF BACK PAIN - The present invention relates to methods of diagnosing and/or treating lower back pain (LBP). In one embodiment, the invention relates to a system for diagnosis of a form of lower back pain in an individual, using a means to identify a type and/or a concentration of one or more inflammatory mediators in the epidural space of the individual. In another embodiment, the invention relates to a system for diagnosis of a form of lower back pain in an individual by identifying a type and/or concentration of one or more inflammatory mediators in the epidural space of the individual, and rendering a diagnosis of the form of lower back pain in the individual based on the presence, absence and/or combination of presences and/or absences of one or more inflammatory mediators in the epidural space of the individual | 2011-08-04 |
20110190244 | METHOD OF TREATMENT OF EGFR INHIBITOR TOXICITY - The invention provides a method of treating and/or preventing a toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy in a subject, the method comprising administering to the subject an effective amount of a steroid sulfatase (STS) inhibitor. The toxicity may be ocular toxicity; or dermatologic toxicity, such as papulopustular rash. The EGFR inhibitor may be selected from the group consisting of: a small molecule; an antibody or derivative or fragment thereof; another agent that targets the extracellular or intracellular domain of the EGFR, such as a tyrosine kinase inhibitor selected from the group consisting of: erlotinib; gefitinib; lapatinib; and any combination thereof. The EGFR inhibitor may also be antibody selected from the group consisting of: cetuximab; panitumumab; and any combination thereof. | 2011-08-04 |
20110190245 | NANOSUSPENSION WITH ANTIFUNGAL MEDICATION TO BE ADMINISTERED VIA INHALATION WITH IMPROVED IMPURITY PROFILE AND SAFETY - The present invention is directed to new nanosuspensions of antifungal azole derivatives, particularly itraconazole, with with improved impurity profile optimized for inhaled administration for the prevention, reversal and medical treatment of fungal infections of the respiratory tract including adjacent lymph nodes. The new formulation which is devoid of particulate inorganic contamination can be safely administered by inhalation. This administration route results in an improved therapeutic effect and reduced side effect profile as compared to the previously used clinical administration route, i.e. oral or parenteral (intravenous) administration. | 2011-08-04 |
20110190246 | ESTRATRIENE DERIVATIVES COMPRISING HETEROCYCLIC BIOISOSTERES FOR THE PHENOLIC A-RING - The present invention is directed to novel pyrazolo-estrien and triazolo-estrien-derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by an estrogen receptor such as hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular diseases, hormone sensitive cancers and hyperplasia (in tissues including breast, endometrium, and cervix in women and prostate in men), endometriosis, uterine fibroids, osteoarthritis; and as contraceptive agents either alone or in combination with a progestogen or progestogen antagonist. The compounds of the invention are selective estrogen receptor modulators. | 2011-08-04 |
20110190247 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR - In its many embodiments, the present invention provides a novel class of cyclopropylchromene derivatives as modulators of a2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the a2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2011-08-04 |
20110190248 | CYCLOHEXYLOXY SUBSTITUTED HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM - The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I) | 2011-08-04 |
20110190249 | THERAPEUTIC METHODS AND USES OF SAPOGENINS AND THEIR DERIVATIVES - The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment. | 2011-08-04 |
20110190250 | EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT - The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema. | 2011-08-04 |
20110190251 | METHOD FOR INHIBITING THE BUILD-UP OF ARTERIAL PLAQUE BY ADMINISTERING FULLERENES - Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes. | 2011-08-04 |
20110190252 | COMPOSITIONS INCLUDING CLAVULANIC ACID AND RELATED METHODS OF USE - Methods of treating a disorder in a subject comprising administering to a subject an elastase inhibitor such as clavulanic acid, sulbactam, or tazobactam are described. | 2011-08-04 |
20110190253 | METHOD FOR TREATING TUBERCULOSIS - The present invention generally relates to methods for treating tuberculosis in a subject comprising administering to the subject an antibiotic in conjunction with clavulanic acid or salt thereof. The antibiotic can be carbapenem (e.g., meropenem or imipenem) or cefuroxime. The present invention also relates to related pharmaceutical compositions and methods for manufacturing said pharmaceutical compositions. | 2011-08-04 |
20110190254 | CEPHALOSPORIN HAVING CATECHOL GROUP - The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows: | 2011-08-04 |
20110190255 | HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 2011-08-04 |
20110190256 | Amine and Ether Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain. | 2011-08-04 |
20110190257 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS - The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2011-08-04 |
20110190258 | ARYL BENZYLAMINE COMPOUNDS - The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them. | 2011-08-04 |
20110190259 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 2011-08-04 |
20110190260 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6, transplantation rejection (e.g. organ transplant rejection) and proliferative diseases. | 2011-08-04 |
20110190261 | MAPK/ERK Kinase Inhibitors - Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: | 2011-08-04 |
20110190262 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use - The present invention relates to compounds defined by formula I | 2011-08-04 |
20110190263 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds of Formula (I): pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 2011-08-04 |
20110190264 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof. | 2011-08-04 |
20110190265 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING QUORUM SENSING - The present invention provides methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5′-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor. The present invention further provides pharmaceutical compositions comprising a sub-bacterial-growth inhibiting amount of a 5′-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor and a pharmaceutically acceptable carrier. | 2011-08-04 |